Compare AbCellera Biologics Inc (ABCL) vs Sony Group Corp (SONY) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
AbCellera Biologics Inc vs Sony Group Corp — how do they compare? AbCellera Biologics Inc trades at $7.23 (market cap $2.35B), while Sony Group Corp trades at $21.22 (market cap $127.11B). The key difference: Sony Group Corp is far larger — about 54.1× AbCellera Biologics Inc's market cap, and Sony Group Corp pays a 0.74% dividend while AbCellera Biologics Inc pays none. Which is the better fit depends on your goals.
| ABCL | SONY | |
|---|---|---|
Market Cap | $2.35B | $127.11B |
Sector | Health | Technology |
52-Week High | $8.12 | $30.26 |
52-Week Low | $2.78 | $19.32 |
Enterprise Value | $1.99B | $123.60B |
Dividend Yield | — | 0.74% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AbCellera Biologics (ABCL) trades at $7.69, down 5.18% today, with a bullish technical signal from moving averages but overbought RSI readings. The company reported a net loss of -$146.41M in 2025, with negative margins, though revenue grew to $75.13M. Recent news highlights a major collaboration with Jazz Pharmaceuticals worth up to $876M, potentially boosting future revenue streams. Analyst consensus is strongly bullish with a $9.67 price target, indicating 25.7% upside.
The outlook hinges on execution of new partnerships and pipeline progress, particularly ABCL635 Phase 2 data expected in Q3 2026. Key risks include persistent cash burn, high valuation multiples despite losses, and biotech sector volatility. Investors should weigh the strong analyst support against fundamental challenges and the stock's current technical overbought condition.
Sony's stock trades at $21.40, up 2.93% today, with a bullish technical signal from moving averages. Recent earnings show mixed results, beating estimates in Q3 and Q4 2025 but missing in Q1 2026. The company reported strong 2025 revenue of $12.96 trillion and net income of $1.14 trillion, though 2026 projections indicate a net loss. Analyst sentiment is positive, with 68.75% recommending buy. Recent news highlights Sony's shift to digital-only game discs by 2028, sparking consumer backlash.
The outlook is cautiously optimistic due to strong analyst support and solid cash flow, but risks include the negative profit margin forecast for 2026 and market reaction to the digital transition. Investors should weigh the company's innovation efforts against execution risks in a competitive landscape.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AbCellera Biologics Inc
AbCellera Biologics Inc is a biotechnology company. It develops antibodies to treat infectious diseases and various other types of diseases. The company's AI-powered technology sources, searches, decodes and analyzes antibody responses to engineer new antibody drug candidates for its partners.
Read more on ABCL →About Sony Group Corp
Sony Group is a conglomerate with consumer electronics roots, which not only designs, develops, produces, and sells electronic equipment and devices, but also is engaged in content businesses, such as console and mobile games, music, and movies. Sony is a global top company of CMOS image sensors, game consoles, professional broadcasting cameras, and music publishing, and is one of the top players on digital cameras, wireless earphones, recorded music, movies, and so on. Sony's business portfolio is well diversified with six major business segments. The company fully consolidated Sony Financial in September 2020, which provides life and non-life insurance, banking, and other financial services.
Read more on SONY →
